Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed. This open-label, phase 3 trial evalua...

Celý popis

Podrobná bibliografie

Vydáno v:	Clinical infectious diseases
Hlavní autoři:	Goswami, Jaya, Cardona, Jose F, Caso, Jorge, Hsu, Denise C, Simorellis, Alana K, Wilson, Lauren, Dhar, Rakesh, Wang, Xiaowei, Kapoor, Archana, Collins, Avi, Righi, Vinicius, Lan, Lan, Du, Jiejun, Zhou, Honghong, Stoszek, Sonia K, Shaw, Christine A, Reuter, Caroline, Wilson, Eleanor, Das, Rituparna
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 23.09.2025
Témata:	mRNA RSV vaccine revaccination respiratory syncytial virus safety immunogenicity
ISSN:	1537-6591, 1537-6591
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!